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Abstract
Objective: Isolated hypogonadotropic hypogonadism (IHH) is a rare disorder with pubertal delay, normal 
(normoosmic-IHH, nIHH) or defective sense of smell (Kallmann syndrome, KS). Other reproductive and non-
reproductive anomalies might be present although information on their frequency are scanty, particularly according 
to the age of presentation.
Design: Observational cohort study carried out between January 2008 and June 2016 within a national network of 
academic or general hospitals.
Methods: We performed a detailed phenotyping of 503 IHH patients with: (1) manifestations of hypogonadism with 
low sex steroid hormone and low/normal gonadotropins; (2) absence of expansive hypothalamic/pituitary lesions or 
multiple pituitary hormone defects. Cohort was divided on IHH onset (PPO, pre-pubertal onset or AO, adult onset) and 
olfactory function: PPO-nIHH (n = 275), KS (n = 184), AO-nIHH (n = 36) and AO-doIHH (AO-IHH with defective olfaction, 
n = 8).
Results: 90% of patients were classified as PPO and 10% as AO. Typical midline and olfactory defects, bimanual 
synkinesis and familiarity for pubertal delay were also found among the AO-IHH. Mean age at diagnosis was 
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significantly earlier and more frequently associated with congenital hypogonadism stigmata in patients with 
Kallmann’s syndrome (KS). Synkinesis, renal and male genital tract anomalies were enriched in KS. Overweight/obesity 
are significantly associated with AO-IHH rather than PPO-IHH.
Conclusions: Patients with KS are more prone to develop a severe and complex phenotype than nIHH. The presence 
of typical extra-gonadal defects and familiarity for PPO-IHH among the AO-IHH patients indicates a common 
predisposition with variable clinical expression. Overall, these findings improve the understanding of IHH and may 
have a positive impact on the management of patients and their families.
Introduction
Isolated hypogonadotropic hypogonadism (IHH) is a rare 
disorder with a still undetermined prevalence, estimated as 
1:4–10 000 males (1), and approximately 3–5 fold lower in 
females (2, 3, 4). IHH is characterized by abnormal pubertal 
development and/or infertility, low sex steroid and low/
inappropriately normal gonadotropin levels (5, 6). However, 
an adult-onset IHH in patients who had previously completed 
their puberty has been also described (2, 7, 8, 9, 10). IHH is 
termed Kallmann’s syndrome (KS) or normosmic IHH (nIHH) 
when associated with a defective or normal sense of smell (6). 
In the recent years the previous view of KS and nIHH as two 
distinct clinical entities has been questioned (11). Although 
the pathogenesis of IHH is still frequently unexplained, 
a strong genetic background (12) is known to be largely 
shared between KS and nIHH. Indeed, these two entities 
may coexist within unique familial settings, thus suggesting 
they may constitute variable phenotypic manifestations of 
shared genetic defects (13, 14, 15, 16). Furthermore, IHH may 
be associated with other developmental anomalies, such 
as midline defects, hearing impairment, renal anomalies, 
bimanual synkinesia in both sexes and micropenis and/
or cryptorchidism in male patients (2, 6). However, there 
is no information on the frequency of the phenotypical 
manifestations of IHH, in particular according to the age of 
presentation or to the nIHH or KS subclassification.
The aim of this study is to give the clinical 
characterization of IHH in the largest cohort ever collected 




The entire cohort consists of 503 subjects (376 males, 
M and 127 females, F) recruited by the NICe group 
since 2008. The study, accomplishing the Declaration 
of Helsinki, was approved by the Ethics Committee 
of the coordinating institution (GR-2008-1137632), 
and all patients or their tutors gave a written informed 
consent. Anonimous patient data, referred to the time 
of diagnosis, before any therapy, were collected either 
prospectively or retrospectively and a clinical database 
was created. Inclusion criteria were: (1) signs/symptoms 
of hypogonadism associated low sex steroid hormone and 
inappropriately low/normal gonadotropins; (2) absence 
of expansive hypothalamic/pituitary lesions or multiple 
pituitary hormone defects (MPHD). Patients with pubertal 
defect were selected among those that did not enter or 
complete spontaneous pubertal development (testes 
volume <12 mL or primary amenorrhea). Adult males were 
selected among the patients presenting with a complete 
pubertal development and the combination of (a) loss of 
libido, (b) erectile dysfunction, (c) loss of spontaneous 
nocturnal erections, (d) testosterone <8 nmol/L with 
low/normal gonadotropins. Adult females were selected 
among the patients presenting with the combination of 
(a) secondary amenorrhea for 6 months < 40 years of age, 
(b) low/normal gonadotropins. All basal blood sampling 
were performed before 09:00 h, after an adequate fasting 
period, and the low hormonal levels were always confirmed 
at least twice. To omit the functional hypothalamic defects, 
exclusion criteria were: (1) body mass index <18.5 kg/m2 
(17); (2) intensive exercise (>5 h/week); (3) chronic illness. 
Patients diagnosed with IHH during adolescence were 
re-examined after therapy withdrawal between 17 and 
20 years, to exclude a constitutional delay of puberty.
Protocols
Patients and/or their parents underwent standard 
interviews on family history, with particular emphasis on 
the recurrence of delayed/absent puberty, hypogonadism 
or olfactory defects, and past medical history. Data 
























178:1 25Clinical Study M Bonomi and others Clinical presentation of IHH 
patients
www.eje-online.org
collected included: (1) pubertal development (Tanner 
stages); (2) testicular volume (TV) by Prader orchidometer 
or ultrasonographic (US) assessement; (3) stretched 
penile length, classified as micropenis according to the 
available cross-sectional normative data (18, 19); (4) 
presence of gynecomastia; (5) presence of orofacial clefts 
or tooth agenesis; (6) presence of bimanual synkinesis; 
(7) hearing or osmic defects. Any signs of puberty in 
the absence of treatment, such as a TV growth ranging 
4–12 mL in males or thelarche in females, was interpreted 
as a sign of partial spontaneous puberty. The appearance 
of menarche in females or a testicular volume >12 mL in 
male was classified as a complete pubertal development. 
Moreover the following additional investigations were 
performed at enrolment: (1) abdomen US for the study 
of potential renal agenesia/hypoplasia; (2) Magnetic 
resonance imaging (MRI) of hypothalamus–pituitary 
region and rhinencephalon (olfactory bulbs, sulci and 
tracts); (3) Olfactory test by the Brief Smell Identification 
Test (BSIT Sensonic, NJ, USA); (4) audiometry test when 
hearing defect was suspected. Furthermore, patients with 
olfactory defect were stratified as hyposmic or anosmic 
respectively, based on a reduction above or below the 50% 
of the normal threshold. Based on clinical assessment, the 
cohort was divided into subgroups: pre-pubertal onset 
(PPO, in patients with IHH onset before 14 years of age) or 
adult-onset (AO, in patients diagnosed in adulthood after 
an uneventful pubertal development); and depending 
on olfactory function. Thus, each subject was classified 
as belonging to one of the following groups: PPO-nIHH, 
KS, AO-nIHH and AO-doIHH (AO-IHH with defective 
olfaction). PPO patients, either KS or nIHH, were further 
divided into those with totally absent (male: TV <4 mL; 
female: absent thelarche) or partial pubertal development 
(male: TV ranging 4–12 mL; female: positive thelarche).
Biochemical assessment
As we recruited patients with a diagnosis obtained up 
to 25  years ago, different methods had been used. In 
the majority of the cases, serum LH, FSH, estradiol 
and testosterone concentrations were measured by 
electrochemiluminescence immunoassay ‘ECLIA’ from 
Roche Diagnostic (Roche Diagnostics GmbH). LH and 
FSH assays had a lower limit of detection of 0.1 IU/L and 
a functional sensitivity of 0.2 IU/L. Elecsys Testosterone II 
test (Calibrator reference: 05200067 190) had a lower limit 
of detection of 0.087 nmol/L and a functional sensitivity 
of 0.4 nmol/L. Elecsys Estradiol III test (Calibrator 
reference: 06656048), had a lower limit of detection of 
18.4 pmol/L, and a functional sensitivity of 85 pmol/L. 
The inter- or intra-assay coefficients of variation were 
<5% in all assays since 2008. Both steroid methods were 
standardized via isotope dilution-gas chromatography/
mass spectrometry.
Statistical methods
Statistical analyses were performed with GraphPad 
Prism 6.0 (GraphPad Software). Data were expressed 
as mean ± s.e. unless otherwise indicated. Continous 
data from different subsets were compared by means of 
Mann–Whitney rank-sum test or Kruskal–Wallis with 
post-hoc Dunn’s multiple comparison test as appropriate. 
Categorical data were tested by the Chi-square or Fisher’s 
exact test as appropriate. All P values were two-sided and 
P < 0.05 was considered significant, although in case of 
multiple comparisons a P value adjusted for the number 
of comparison was applied. Sex of the patients was 
consider a factor in the statistical analysis as appeared in 
the results section and the correlated figures and tables. 
Pairwise comparisons were always performed between 
KS vs PPO-nIHH and AO-doIHH vs AO-nIHH. Multiple 
comparison, including also the PPO-nIHH vs AO-nIHH 
and KS vs AO-doIHH contrasts were only performed for 
the body mass index and the hormone values variables.
Results
Cohort composition
The cohort composition and clinical information are 
reported in Table 1. A total of 459 (91.2%) patients were 
presenting as PPO-IHH (116 F and 343 M), while 44 (8.8%) 
patients who completed puberty before the reproductive 
axis failure, were classified as AO-IHH (11 F and 33 M). 
The 26.5% of the male PPO-group (n = 91) presented with 
a partial spontaneous pubertal development, whereas 
73.5% (n = 252) had no signs of spontaneous puberty at 
>17 years of age. All female PPO patients, instead, were 
presenting a complete absence of pubertal development. 
A total of 192 (47 F and 145 M) patients were referred to 
have a smell defect, whereas 311 (80 F and 231 M) patients 
formed the normosmic groups.
Age, familiarity and body mass index (BMI) 
at diagnosis
The mean age at diagnosis was 19.9 ± 0.5  years and 
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a significantly earlier diagnosis in patients with KS. No 
differences between males and females were observed in 
any subgroup except in the AO-nIHH (Table 1).
BMI did not differ among the groups, except for 
AO-nIHH vs PPO-nIHH (adj. P = 0.0159). Moreover, 
stratifying the groups in normal-weight (BMI <25 kg/m2), 
overweight (BMI 25–29.99 kg/m2) or obese (BMI ≥30 kg/
m2) subjects it became evident that AO groups present a 
higher percentage of overweight/obese then PP-groups. 
Considering the sex of the patients, we observed 
statistically significant higher percentages of normal-
weight patients in the female than that in male PPO-
nIHH group (Table 1). The prevalence of obesity among 
the patients with AO-IHH is higher as of the one reported 
either in the male (15.6 vs 11.5%) or female (20.0 vs 9.3%) 
adult Italian population by the last survey of the National 
Institute of Statistics (www.istat.it).
Most cases were sporadic, however a familiarity with 
IHH was present in 19.0 or 29.6% among the patients with 
adult or PP onset respectively, and was more common in 
the groups with osmic defects (Table 1).
Hormone profiles
Patient hormone profiles were evaluated at diagnosis. 
LH/FSH levels were evaluated at baseline and after GnRH 
stimulation in 59.7% and 59.4% of the KS and nIHH 
subjects respectively. LH and FSH basal mean values 
(Fig.  1A) were below the lower limit of normal in PPO 
groups and low-normal in AO groups. No significant LH 
differences between either KS vs PPO-nIHH or AO-doIHH 
vs AO-nIHH were observed, whereas basal FSH values 
were significantly higher in PPO-nIHH compared to KS. 
Moreover, both LH and FSH basal values were significantly 
different between KS and AO-doIHH (P = 0.001) or PPO- 
and AO-nIHH (P = 0.00001). Acute GnRH stimulation 
showed a blunted response (Fig. 1B) in PPO groups and 
a normal response in the AO groups for both LH and 
Table 1 Cohort composition.
 PPO-nIHH KS P value AO-nIHH AO-doIHH P value P value overall comparison
Male (n) 202 141 – 29 4 – –
 Complete puberty 0 0 – 29 4 – –
 Partial puberty 52 39 – 0 0 – –
 No puberty 150 102 – 0 0 – –
Female (n) 73 43 – 7 4 – –
 Complete puberty 0 0 – 7 4 – –
 Partial puberty 0 0 – 0 0 – –
 No puberty 73 43 – 0 0 – –
Ratio F:M 1:2.7 1:3.3 – 1:4.1 1:1 – –
Age at diagnosis (year) 19.9 ± 0.5 18.3 ± 0.7 0.0227 35.7 ± 2.7 33.1 ± 6.3 ns –
 M(year) 20.6 ± 0.7 18.4 ± 0.8 0.0253 37.7 ± 2.4 29.7 ± 5.0 ns –
 F(year) 17.9 ± 0.6 17.8 ± 1.0 ns 22.3 ± 2.4 35.7 ± 10.9 ns –
BMI (kg/m2) 24.3 ± 0.3 24.8 ± 0.4 ns 25.6 ± 0.8 25.9 ± 1.8 ns 0.0259
  ≤ 19 to < 25 (%) 65.9 52.4 0.0118 44.1 37.5 ns 0.0074
  M(%) 60.5 50.4 – 42.8 25.0 – 0.0986
  F(%) 81.3 59.4 ns 50.0 50.0 ns 0.0367
 ≤ 25 to < 30 (%) 20.8 30.8 ns 41.2 37.5 ns 0.0189
  M(%) 23.9 31.5 – 42.8 50.0 – 0.0876
  F(%) 11.9 28.1 – 33.3 25.0 – 0.1101
 ≥ 30 (%) 13.3 16.8 – 14.7 25.0 – 0.5515
  M(%) 15.6 18.1 – 14.3 25.0 – 0.7769
  F(%) 6.8 12.5 – 16.7 25.0 – 0.2677
Familial recurrence (%) 24.2 36.8 0.0077 14.7 37.5 ns 0.0081
 M(%) 22.4 35.1 0.0190 10.7 25.0 ns 0.0147
 F(%) 29.0 42.5 – 33.0 50.0 – 0.6762
Comparisons for ‘age at diagnosis’ were carried out using Mann–Whitney test: a P value of 0.025 was considered as critical value after multiple 
adjustments (0.05/2). The P value overall comparison refers to an initial contrast of the four groups: when statistically significant, pairwise assessments 
were performed between PPO-nIHH and KS or AO-nIHH and AO-doIHH. Comparisons for BMI (kg/m2) were performed using the Kruskal–Wallis test with 
Dunn’s post-hoc test. All other contrasts among categorical variables were performed using the Chi-square or Fisher’s exact test as appropriate with a 
P value of 0.025 as indicated above. Comparisons of male and female subgroups were made and two were significant at the 5% level: in group AO-nIHH 
the P value for ‘age at diagnosis’ was 0.0054; in group PPO-nIHH the P value for ‘19 ≤ BMI < 25 (%)’ was 0.0039.
AO, adult-onset; AO-doIHH, AO-IHH with defective olfaction; F, female; KS, Kallmann syndrome; M, male; nIHH, normosmic Isolated Hypogonadotropic 
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FSH, with significantly different LH peak between PPO- 
and AO-nIHH (P = 0.0001). No sex differences were noted 
either for basal or stimulated gonadotropin levels in the 
different groups. In male PPO groups, gonadotropin levels 
were also stratified according to the partial or complete 
absence of pubertal development (Supplementary Fig. 1, 
see section on supplementary data given at the end of 
this article). Mean basal and stimulated LH values were 
statistically different according to the stage of pubertal 
development (Supplementary Fig.  1), independently of 
the olfactory status. No differences in mean FSH values 
were recorded, except basal FSH values between nIHH 
vs KS absent puberty groups. Testosterone levels were 
below the normal range in all male patients (Fig.  1C). 
A significant difference in testosterone levels was only 
observed in the following comparisons: PPO- vs AO-nIHH 
(P = 0.00001) and KS vs AO-doIHH (P = 0.01). Testosterone 
levels were low in all the male PPO groups. Estradiol levels 
were similar and below the normal range in all female 
groups (Fig. 1D).
Developmental anomalies
Information on these defects was recorded in 87–100% 
of the cases (Table 2). A significantly higher percentage of 
bimanual synkinesia and renal anomalies was seen in KS 
compared to PPO-nIHH group. Orofacial clefts or tooth 
agenesis are significantly more represented in the groups 
with osmic defect (KS and doIHH) than that in normosmic 
groups (PPO-nIHH and AO-nIHH) (χ2 = 4.04; P = 0.0445).
No particular differences were noted for all the 
considered developmental anomalies between sexes, 
except for the renal anomalies that were exclusively 
affecting the males.
Analysis of male genital tract anomalies data (Table 3) 
showed a high percentage of cryptorchidism in PPO 
groups associated with a small testicular volume at 
diagnosis. Interestingly, micropenis or cryptorchidism 
(either mono- or bi-lateral) were significantly more 
represented in KS compared to PPO-nIHH. Nonetheless, 
cryptorchidism was present in a higher percentage of 
Figure 1
Hormone profile. Serum LH, FSH and sex 
steroids levels of the whole IHH cohort 
(n = 503; male, n = 376; female, n = 127). 
Results represent the baseline (A) and 
peak stimulated (B) values of the two 
gonadotropins and the baseline values of 
male testosterone (C) and female 
estradiol (D). Gonadotropin stimulation 
was evaluated following administration 
of a standard dose of 100 mg GnRH and 
blood samples for FSH and LH were 
obtained at the 0′, 30′, 60′, 90′ and 
120′ min. Gonadotropin normal basal 
values are (IU/L): LH >1.7; FSH >1.5. 
Peri-pubertal peak normal range: LH/
FSH = 2–3 fold × basal level; adulthood 
peak normal range: LH = 2–5 fold × basal 
level; FSH: 1–2 fold × basal level. Sex 
steroid normal basal values are: 
Testosterone: 9.9–27.8 nmol/L; Estradiol: 
36–470 pmol/L. PPO, pre-pubertal onset; 
nIHH, normosmic Isolated 
Hypogonadotropic Hypogonadism; KS, 
Kallmann syndrome; AO, adult-onset; 
AO-doIHH, AO-IHH with defective 
olfaction. Comparisons were carried out 
using a Kruskal–Wallis with post-hoc 
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patients with a complete absent rather than that in those 
with a partial pubertal development. In general, testicular 
volume at diagnosis was smaller in patients with osmic 
defect than that in normosmic patients with a difference 
close to be statistically significant only between the two 
PPO-subgroups (P = 0.0437).
Hypothalamus–pituitary MRI imaging
These investigations were performed in all cases. MRI of 
the hypothalamic–pituitary region was normal in almost 
all patients irrespective of the groups (Fig.  2). However, 
pituitary hypoplasia, or partial empty sella or non-
secreting incidental microlesion were seen in a minority 
of subjects, with similar percentages among groups or 
among sexes (Fig. 2).
Olfactory evalutation
An accurate olfactory evaluation of the patients was 
performed by smell test (in 157 KS and 175 nIHH patients) 
and/or MRI (in 86 KS and 71 nIHH patients). Results of 
the smell test were compared to percentile norms, based 
upon 4000 subjects matched for sex and range of age, 
reported in the B-SIT Administration Manual. All nIHH 
patients presented a normal smell identification score. 
In contrast, KS and AO-doIHH had a defective sense of 
smell, with a similar distribution of anosmia or hyposmia 
(Fig.  3A). The MRI evaluation of olfactory structures 
was normal in the nIHH groups, whereas it was variably 
affected in KS patients with pre-pubertal or adult-onset 
of hypogonadism. A complete aplasia or hypoplasia of 
the rhinencefalon was seen in the large majority of these 
subjects (Fig.  3B). It appears that the subgroup of KS 















P value overall 
comparison
Bimanual synkinesis % (n) 2.5 (6/234) 10.9 (19/174) 0.0006 6.1 (2/33) 12.5 (1/8) ns 0.0031
Orofacial clefts and/or 
tooth agenesis % (n)
9.8 (23/235) 14.9 (26/174) ns 0 (0/35) 12.5 (1/8) ns 0.0296
Renal anomalies % (n) 0.4 (1/231) 11.5 (20/174) <0.0001 0 (0/35) 0 (0/8) – <0.0001
Hearing loss % (n) 5.2 (12/231) 7.0 (12/172) – 0 (0/35) 0 (0/8) – 0.4447
P value overall comparison refers to an initial comparison of the four groups: when statistically significant, pairwise comparisons were performed 
between PPO-nIHH and KS or AO-nIHH and AO-doIHH. In this case, a P value of 0.025 was considered as critical value after multiple adjustments (0.05/2). 
Comparisons among categorical variables were performed using the Chi-square or Fisher’s exact test as appropriate.
*The possibility to describe other associated phenotypes, such as daltonism, coloboma, nystagmus, external ear malformations, clinodactyly or vertebral 
malformations, was given as an open field and they were recorded in a minority of cases (6 KS, 6 PPO-nIHH and 1 AO-nIHH patients) although it is not 
possible to define the frequency.
AO, adult-onset; AO-doIHH, AO-IHH with defective olfaction; KS, Kallmann syndrome; nIHH, normosmic Isolated Hypogonadotropic Hypogonadism; 
PPO, pre-pubertal onset.
Table 3 Male genital tract anomalies.
 PPO-nIHH KS P value AO-nIHH AO-doIHH P value P value overall comparison
Micropenis (%) 2.4 7.8 ns 0 0 – –
 Partial puberty (%) 0 5.1 ns – – – –
 Absent puberty (%) 3.3b 8.8b ns – – – –
Male cryptorchidism (%) 21.9 52.7 <0.0001 7.4 0 ns <0.0001
 Monolateral(%) 4.2 24.0 <0.0001 3.7 0 ns <0.0001
 Bilateral (%) 17.7 28.7 ns 3.7 0 ns 0.0078
 Partial puberty (%) 7.8 34.2 0.002 – – – –
 Absent puberty (%) 28.3a 60.4a <0.0001 – – – –
TV (mL) 4.9 ± 0.2 4.2 ± 0.2 ns 18.6 ± 0.7 16.1 ± 0.5 ns <0.0001
 Partial puberty (mL) 8.6 ± 0.2 8.0 ± 0.3 ns – – – –
 Absent puberty (mL) 2.5 ± 0.1 2.21 ± 0.1 0.02 – – – –
P value overall comparison refers to an initial comparison of the four groups: when statistically significant, pairwise comparisons were performed 
between PPO-nIHH and KS or AO-nIHH and AO-doIHH. Comparisons among all categorical variables were performed using the Chi-square or Fisher’s 
exact test as appropriate and a P value of 0.025 was considered as critical value after multiple adjustments (0.05/2). ‘TV’ contrasts were carried out using 
the Kruskal–Wallis test with Dunn’s multiple adjustment test.
aP < 0.01, absent puberty vs partial puberty. bP = ns, absent puberty vs partial puberty.
AO, adult-onset; AO-doIHH, AO-IHH with defective olfaction; KS, Kallmann syndrome; nIHH, normosmic Isolated Hypogonadotropic Hypogonadism; 
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patients with totally absent puberty are those displaying 
the more compromised olfactory structure whereas the 
AO-doIHH (with a normal pubertal development) were 
the less compromised. No significant differences were 
noted among sexes.
Discussion
We report the clinical presentation of the largest cohort 
of IHH patients so far described. The cohort was recruited 
in various academic and general hospitals across all Italy, 
thus reflecting the existent clinical practice and included 
patients experiencing the failure of the reproductive 
axis before pubertal development (either with partial or 
complete absent sexual development) or after spontaneous 
sexual maturation, thus highlighting the wide clinical 
spectrum of IHH (2, 20). The olfaction defects are more 
frequently associated with a complete GnRH deficiency 
and with non-reproductive manifestations. Nevertheless, 
the systematic evaluation of olfactory function 
surprisingly revealed the existence of morphological/
functional defects in olfactory structures also among 
patients with an adult onset of IHH. Interestingly, 
familiarity for IHH was detected in variable but significant 
percentages of patients with pre-pubertal or adult onset of 
central hypogonadism suggesting a common inheritable 
predisposition between these two conditions that can be 
thus considered two extremes of a clinical spectrum of 
manifestations affecting the GnRH function.
An accurate evaluation of the smell function was 
performed in a high number of patients previously 
classified as KS or nIHH, confirming the data reported at 
diagnosis. After exclusion of 5 nIHH patients with turbinate 
hypertrophy, none of the patients classified as nIHH 
presented any defect in the sense of smell at olfactory test or 
rhinencephalon MRI (Fig. 3A and B). Among the KS patients, 
the percentage of aplastic olfactory structure tended to be 
associated with a more severe hypogonadal state.
Systematic neuroimaging of the hypothalamic–
pituitary region revealed pituitary defects, such as 
hypoplasia, partial empty sella or pituitary non-
functioning micro-lesions in a minority of cases. These 
findings were similarly distributed in the different groups 
and were non-associated with specific features.
Interestinlgy, patients with KS were diagnosed at an 
earlier age and have a more frequent familial recurrence 
Figure 2
Hypothalamus–pituitary MRI investigations. Results represent 
the hypothalamus–pituitary MRI investigations in the four 
groups. PPO, pre-pubertal onset; nIHH, normosmic Isolated 
Hypogonadotropic Hypogonadism; KS, Kallmann syndrome; 
AO, adult-onset; AO-doIHH, AO-IHH with defective olfaction.
Figure 3
Olfactory testing (A) and MRI investigations of the olfactory 
structure (B) in the IHH cohort. PPO, pre-pubertal onset; nIHH, 
normosmic Isolated Hypogonadotropic Hypogonadism; KS, 
Kallmann syndrome; AO, adult-onset; AO-doIHH, AO-IHH with 
defective olfaction; absent, completely absent pubertal 
development; partial, partial pubertal development; 
complete, complete pubertal development (= adult onset). 
Comparisons among categorical variables were performed 
between KS and AO-doIHH using the Chi-square or Fisher’s 
exact test as appropriate and a P value of 0.025 was 
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than nIHH counterpart. Such differences were statistically 
significant in the PPO groups and the trend was conserved 
also in AO groups. These data are in agreement with the 
more severe neonatal phenotype of patients with KS, and 
perhaps with a more frequent involvement of inheritable 
genetic defects with a higher degree of expressivity and 
penetrance. Some authors (21, 22, 23) reported a similar 
prevalence of cryptorchidism between KS and nIHH 
groups. In our cohort, congenital micropenis was present 
only in PPO groups, as expected (10, 24, 25), but the 
prevalence of male genital tract anomalies, including 
micropenis and cryptorchidism (Table 3), was significantly 
higher in patients with KS, thus indicating a more severe 
intrauterine androgen deficiency in patients with KS. All 
together, these findings support the idea of an hormonal 
condition that is generally worse among patients with 
KS. The frequency of micropenis at diagnosis is probably 
underestimated in our series. This is possibly due to the 
collection of retrospective data in multiple pediatric 
and adult centers where other parameters (e.g., pre-
treatment biochemical values) could be recovered, but the 
micropenis could not always be confirmed by a physical 
determination of this parameter.
Patients with KS also had a higher percentage of 
associated developmental anomalies (Table  2). Our data 
regarding the sensorineural hearing loss, which was 
present only in PPO groups and with a slightly higher 
percentage in patients with KS, were partially discordant 
with previous literature, reporting the presence of high 
percentage of hearing loss in patients with KS (25, 26) 
and a total absence in nIHH (24). More importantly, the 
renal anomalies were only present in PPO groups and 
particularly in the male patients with KS. Such association 
had been reported in the past when renal dysgenesis 
was considered as a hallmark of the X-linked form of KS 
(27, 28) although such malformations have been described 
in other KS autosomic dominant/recessive forms. Our 
findings strongly indicate that kidney anomalies should 
be suspected only in males with osmic defects.
A limitation of our retrospective study is represented 
by impossibility to have uniform biochemical analyses. 
Nevertheless, the majority of the patients had been 
evaluated with the same methods for gonadotropins 
and steroids, and no differences in the distribution 
among the various subgroups were seen when other 
methods had been used. Altogether, patients with KS and 
nIHH of the present cohort showed overlapping levels 
of gonadotropins and sex steroids (Fig.  1), confirming 
previous findings (2, 6). Reproductive axis activity was 
indeed more severely affected in PPO- than that in AO 
groups. In fact, the acute GnRH stimulation lead to 
a more defective LH response in PPO- than that in AO 
groups. Moreover, we found significantly lower LH levels 
in the male patients with a complete defect in comparison 
with those with a partial pubertal development. Although 
basal FSH levels were significantly higher in nIHH than 
that in KS subgroups with absent pubertal development, 
GnRH function appears similarly affected among nIHH 
and KS groups: in particular FSH peak values after GnRH 
stimulation were comparable among the four groups. 
Thus, a biochemical marker and/or dynamic test able to 
differentiate KS/nIHH is still missing (2).
We observed that around 40% of the patients in PPO 
groups were overweight/obese (OW/OB). These data are 
quite similar to what reported in a previous study (10), but 
the most interesting finding on the association with BMI 
was detected among the AO groups. Indeed, the prevalence 
of obese subjects in the AO-IHH patients was double than 
the one reported in a recent survey on the whole Italian 
population, and the majority of the OW/OB patients in 
the PPO and AO groups were males. It is known that an 
excess of visceral fat may affect the pulsatile gonadotropin 
release from the pituitary (7). Moreover, a recent study 
in a rabbit model demonstrated that a high-fat diet can 
induce a metabolic syndrome and a central hypogonadism 
associated with a reduced hypothalamic expression of 
KISS1 and KISS1R (29). Thus, our data are in accord with 
the results obtained in animal models supporting the 
existence of common mechanisms accounting for GnRH 
function and metabolic regulation (30). In addition, 
overweight/obesity might represent an acquired cofactor, 
involved in the onset of IHH among adult subjects that are 
naturally prone to develop a central failure of the gonadal 
axis. Thus, the presence of congenital defects in the PPO-
group strongly affects the development, migration and/or 
activation of GnRH-secreting neurons leading to a severe 
phenotype with an early onset, independently of the 
body weight, whereas overweight/obesity may facilitate 
a delayed IHH onset in carriers of susceptibility alleles 
with a limited impact on GnRH function. Accordingly, 
a major interaction between genes and behavior in IHH 
has been previously reported in females with functional 
hypothalamic amenorrhea (31).
In conclusion, we provide the frequency of several 
IHH clinical characteristics at presentation in the largest 
cohort ever reported. We demonstrate that IHH clinical 
spectrum may be even more heterogeneous than 
previously considered. Despite the existence of a largely 
common pathogenic background, patients with KS are 
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than patients with nIHH. Fot the first time, we describe 
that AO-IHH is not always a sporadic disease (as previously 
reported in ref. (9, 10)), and together with PPO-IHH 
they may represent two extremes of a clinical spectrum: 
they share phenotypical traits (familiarity, olfactory 
and midline defects, or bimanual synkinesis) and may 
therefore have a common predisposition. In AO-IHH, 
the presence of obesity is double than that in general 
Italian population and more frequent than that in the 
pre-pubertal forms, and could thus constitute a relevant 
factor contributing to the adult onset of the HPG failure. 
All together, these findings improve the understanding of 
this disease that may have a positive impact on the future 
management of IHH patients and their families.
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